Literature DB >> 6734727

[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.

B Bokobza, M Ruberg, B Scatton, F Javoy-Agid, Y Agid.   

Abstract

The density of D2-type dopamine receptors, measured by the binding of [3H]spiperone was normal in the substantia nigra, caudate nucleus and nucleus accumbens of Parkinsonian subjects and above control levels in the putamen, in spite of massive lesions of the dopaminergic neurons. Dopamine levels were reduced in the putamen, caudate nucleus, and nucleus accumbens by 97, 85 and 68%, respectively and by 78 and 93% in the pars compacta and pars reticulata of the substantia nigra. HVA levels were much less affected suggesting that increased activity of the remaining dopaminergic neurons compensated to some extent for the lesions. Neuroleptic treatment and the presence of dementia in the Parkinsonian subjects affected [3H]spiperone binding and dopamine concentrations. Dopamine and HVA levels in the striatum of subjects with supranuclear palsy indicate that the nigrostriatal system was lesioned to the same degree in this disease as in idiopathic Parkinsonism, but spiperone binding was reduced by half in all the structures studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734727     DOI: 10.1016/0014-2999(84)90238-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography.

Authors:  H Karbe; M Grond; M Huber; K Herholz; J Kessler; W D Heiss
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

2.  Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.

Authors:  Keita Ishiwari; Lisa J Madson; Andrew M Farrar; Susana M Mingote; John P Valenta; Michael D DiGianvittorio; Lauren E Frank; Merce Correa; Jörg Hockemeyer; Christa Müller; John D Salamone
Journal:  Behav Brain Res       Date:  2006-12-21       Impact factor: 3.332

Review 3.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

4.  New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.

Authors:  Michael A Kelberman; Elena M Vazey
Journal:  Curr Pharmacol Rep       Date:  2016-09-28

5.  Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.

Authors:  S Papapetropoulos; D C Mash
Journal:  J Neural Transm (Vienna)       Date:  2006-12-07       Impact factor: 3.575

6.  Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function.

Authors:  Anders H Andersen; Peter A Hardy; Eric Forman; Greg A Gerhardt; Don M Gash; Richard C Grondin; Zhiming Zhang
Journal:  Neurobiol Aging       Date:  2014-10-16       Impact factor: 4.673

7.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

8.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 9.  Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism.

Authors:  John D Salamone; Keita Ishiwari; Adrienne J Betz; Andrew M Farrar; Susana M Mingote; Laura Font; Jörg Hockemeyer; Christa E Müller; Mercè Correa
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

10.  L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.

Authors:  M Guttman; P Seeman
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.